CathVision, a medical technology company developing electrophysiology (EP) solutions, yesterday announced it has obtained $7.2 million in funding from existing investors. The funding will help the company advance commercial operations for the ECGenius System and “support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures.”

"Our investors have witnessed the evolution of our company and technology in recent years," said Mads Matthiesen, CEO, CathVision. "Reinvesting in the company demonstrates confidence in our innovation, ongoing development, and ability to advance adoption of the ECGenius System throughout the United States as we focus on empowering physicians to diagnose, characterize, and treat cardiac arrhythmias more effectively. We are expanding our sales team, building our US presence, and furthering the development of analytic modules."

The ECGenius System is an EP recording system designed to guide and enhance ablation therapy through high-fidelity and low-noise EP signals.

“The ECGenius System acquires electrogram signals with minimal baseline noise, providing electrophysiologists with a clear and unobstructed view of electrical activation associated with the complexities of cardiac arrhythmias,” according to the company website.

When using the system, IEGMs from radiofrequency probe are artifact free, according to CathVision, which allows physicians to observe minor but significant signal modification during RF application. Additionally, research from the Institute for Clinical and Experimental Medicine concluded positive paradigm-shifting capabilities of the ECGenius System. With the system receiving FDA 510(k) clearance in May of this year, it is currently available in limited market release, but not approved for sale in the European Union.

"Cardiac ablation is one of the fastest growing markets in healthcare; treatment efficiency and efficacy must improve for physicians to deliver the best possible care for patients with atrial fibrillation and other cardiac arrhythmias," said Matthieu Bocquet, founding partner, Lumine Capital. "CathVision's modern and precise EP recording technology brings more clarity to physicians by delivering clear signals that can be accurately interpreted. This is a necessary step to improve treatment outcomes."

The company is currently part of a clinical trial with the University of Ghent to investigate the automated assessment of pulmonary vein isolation (PVI) using its first licensed AI algorithm, a PVI analyzer, in combination with the ECGenius System. The PVISION trial includes 90 patients enrolled at four sites in Belgium and France.

“Today’s complex cardiac ablation procedures involve the insertion of multiple electrode catheters into the heart in order to collect and interpret thousands of cardiac signals,” said clinical trial principal investigator Mattias Duytschaever, MD, PhD, AZ Sint-Jan, Bruges, Belgium. “Because the ECGenius System provides us with exceptional low-noise, high-quality signals, we will be able to better examine the efficacy of using the PVI analyzer algorithm during this particular trial to determine if electrical isolation of the pulmonary veins has been achieved. This creates the possibility of an automated, objective, and standardized endpoint for the PVI procedure, which could lead to improved patient outcomes.”